Cathepsins B, H, L and cysteine protease inhibitors in malignant prostate cell lines, primary cultured prostatic cells and prostatic tissue

European Journal of Cancer

Volumn 35, Issue 1, 1999, Pages 138-144

  Friedrich, B ^a   Jung, K ^a   Lein, M ^a   Turk I ^a   Rudolph, B ^a   Hampel, G ^a   Schnorr, D ^a   Loening, S A ^a  

^a CHARITÉ UNIVERSITÄTSMEDIZIN BERLIN   (Germany)

Author keywords

Cathepsins; Cysteine protease; DU 145; Inhibitor; LNCaP; PC 3; Prostate carcinoma

Indexed keywords

CATHEPSIN B; CATHEPSIN H; CATHEPSIN L; CYSTEINE PROTEINASE INHIBITOR;

ADULT; AGED; ARTICLE; CANCER CELL CULTURE; CLINICAL ARTICLE; ENZYME ACTIVITY; ENZYME ANALYSIS; FLUOROMETRY; HUMAN; HUMAN TISSUE; MALE; PRIORITY JOURNAL; PROSTATE CANCER; PROSTATECTOMY; TRANSURETHRAL RESECTION;

ADULT; AGED; AGED, 80 AND OVER; CATHEPSIN B; CATHEPSINS; CYSTEINE ENDOPEPTIDASES; CYSTEINE PROTEINASE INHIBITORS; ENDOPEPTIDASES; HUMANS; MALE; MIDDLE AGED; NEOPLASM PROTEINS; PROSTATIC NEOPLASMS; TUMOR CELLS, CULTURED;

EID: 0032994323     PISSN: 09598049     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0959-8049(98)00273-1     Document Type: Article

References (41)

1. Calkins C.C., Sloane B.F. Mammalian cysteine protease inhibitors: biochemical properties and possible roles in tumor progression. Biol Chem Hoppe Seyler. 376:1995;71-80.
2. Uchiyama Y., Waguri S., Sato N., Watanabe T., Ishido K., Kominami E. Review: cell and tissue distribution of lysosomal cysteine proteinases, cathepsins B, H, and L, and their biological roles. Acta Histochem Cytochem. 27:1994;287-308.
3. Buck M.R., Karustis D.G., Day N.A., Honn K.V., Sloane B.F. Degradation of extracellular-matrix proteins by human cathepsin B from normal and tumour tissues. Biochem J. 282:1992;273-278.
4. Turk B, Bieth JG, Bjork I, et al. Regulation of the activity of lysosomal cysteine proteinases by pH-induced inactivation and/or endogenous protein inhibitors, cystatins. Biol Chem Hoppe Seyler 1995, 376, 225-230.
5. Henskens Y.M., Veerman E.C., Nieuw Amerongen A.V. Cystatins in health and disease. Biol Chem Hoppe Seyler. 377:1996;71-86.
6. Benitez Bribiesca L., Martinez G., Ruiz M.T., Gutierrez Delgado F., Utrera D. Proteinase activity in invasive cancer of the breast. Arch Med Res. 26:1995;S163-S168.
7. Campo E, Munoz J, Miquel R, et al. Cathepsin B expression in colorectal carcinomas correlates with tumor progression and shortened patient survival. Am J Pathol 1994, 145 301-309.
8. Ebert W., Knoch H., Werle B., Trefz G., Muley T., Spiess E. Prognostic value of increased lung tumor tissue cathepsin B. Anticancer Res. 14:1994;895-899.
9. Budihna M, Strojan P, Smid L, et al. Prognostic value of cathepsins B, H, L, D and their endogenous inhibitors stefins A and B in head and neck carcinoma. Biol Chem Hoppe Seyler 1996, 377, 385-390.
10. Chauhan S.S., Goldstein L.J., Gottesman M.M. Expression of cathepsin L in human tumors. Cancer Res. 51:1991;1478-1481.
11. Chambon M, Rebillard X, Rochefort H, et al. Cathepsin D cytosolic assay and immunohistochemical quantification in human prostate tumors. Prostate 1994, 24, 320-325.
12. Sinha A.A., Gleason D.F., Staley N.A., Wilson M.J., Sameni M., Sloane B.F. Cathepsin B in angiogenesis of human prostate: an immunohistochemical and immunoelectron microscopic analysis. Anat Rec. 241:1995;353-362.
13. Sinha A.A., Wilson M.J., Gleason D.F., Reddy P.K., Sameni M., Sloane B.F. Immunohistochemical localization of cathepsin B in neoplastic human prostate. Prostate. 26:1995;171-178.
14. Weiss R.E., Fair W.R., Cordon-Cardo C. Characterization of protease expression in human prostate cancer cell lines. Int J Oncol. 5:1994;973-978.
15. UICC. TNM Klassifikation maligner Tumoren, 4th ed. Berlin, Springer, 1992, 141-165.
16. Peehl DM. Culture of human prostatic epithelial cells. In Freshney RI, ed. Culture of Epithelial Cells. New York, Wiley-Liss, 1992, 159-180.
17. Cronauer M.V., Klocker H., Talasz H., et al. Inhibitory effects of the nucleoside analogue gemcitabine on prostatic carcinoma cells. Prostate. 28:1996;172-181.
18. Jung K, Seidel B, Rudolph B, et al. Antioxidant enzymes in malignant prostate cell lines and in primary cultured prostatic cells. Free Radic Biol Med 1997, 23, 127-133.
19. Kaighn M.E., Narayan K.S., Ohnuki Y., Lechner J.F., Jones L.W. Establishment and characterization of a human prostatic carcinoma cell line (PC-3). Invest Urol. 17:1979;16-23.
20. Stone K.R., Mickey D.D., Wunderli H., Mickey G.H., Paulson D.F. Isolation of a human prostate carcinoma cell line (DU 145). Int J Cancer. 21:1978;274-281.
21. Horoszewicz JS, Leong SS, Kawinski E, et al. LNCaP model of human prostatic carcinoma. Cancer Res 1983, 43, 1809-1818.
22. Barrett AJ, Kirschke H. Cathepsin B, cathepsin H, and cathepsin L. In Colowick SP, Kaplan NO, eds. Methods in Enzymology. New York, Academic Press, 1981, 535-561.
23. Barrett AJ, Kembhavi AA, Brown MA, et al. L-trans-epoxysuccinyl-leucylamido(4-guanidino)butane (E-64) and its analogues as inhibitors of cysteine proteinases including cathepsins B, H and L. Biochem J 1982, 201, 189-198.
24. Lah TT, Kokalj-Kunovar M, Strukelj B, et al. Stefins and lysosomal cathepsins B, L and D in human breast carcinoma. Int J Cancer 1992, 50, 36-44.
25. Mason R.W., Green G.D., Barrett A.J. Human liver cathepsin L. Biochem J. 226:1985;233-241.
26. Dunn MJ. Determination of total protein concentration. In Harris ELV, Angal S, eds. Protein Purification Methods. Oxford, IRL Press, 1992, 10-18.
27. Schwartz M.K. Tissue cathepsins as tumor markers. Clin Chim Acta. 237:1995;67-78.
28. Wilson M.J. Proteases in prostate development, function, and pathology. Microsc Res Tech. 30:1995;305-318.
29. Farinati F, Herszenyi L, Plebani M, et al. Increased levels of cathepsin B and L, urokinase-type plasminogen activator and its inhibitor type-1 as an early event in gastric carcinogenesis. Carcinogenesis 1996, 17, 2581-2587.
30. Sheahan K., Shuja S., Murnane M.J. Cysteine protease activities and tumor development in human colorectal carcinoma. Cancer Res. 49:1989;3809-3814.
31. Kos J, Smid A, Krasovec M, et al. Lysosomal proteases cathepsins D, B, H, L and their inhibitors stefins A and B in head and neck cancer. Biol Chem Hoppe Seyler 1995, 376, 401-405.
32. Shuja S., Murnane M.J. Marked increases in cathepsin B and L activities distinguish papillary carcinoma of the thyroid from normal thyroid or thyroid with non-neoplastic disease. Int J Cancer. 66:1996;420-426.
33. Sloane B.F., Honn K.V., Sadler J.G., Turner W.A., Kimpson J.J., Taylor J.D. Cathepsin B activity in B16 melanoma cells: a possible marker for metastatic potential. Cancer Res. 42:1982;980-986.
34. Kirschke H, Clausen T, Göhring B, et al. Concentrations of lysosomal cysteine proteases are decreased in renal cell carcinoma compared with normal kidney. J Cancer Res Clin Oncol 1997, 7, 402-406.
35. Bartsch G., Muller H.R., Oberholzer M., Rohr H.P. Light microscopic stereological analysis of the normal human prostate and of benign prostatic hyperplasia. J Urol. 122:1979;487-491.
36. Marks L.S., Treiger B., Dorey F.J., Fu Y.S., deKernion J.B. Morphometry of the prostate: I. Distribution of tissue components in hyperplastic glands. Urology. 44:1994;486-492.
37. Howie A.J., Burnett D., Crocker J. The distribution of cathepsin B in human tissues. J Pathol. 145:1985;307-314.
38. Festuccia C, Vincentini C, di Pasquale AB, et al. Plasminogen activator activities in short-term tissue cultures of benign prostatic hyperplasia and prostatic carcinoma. Oncol Res 1995, 7, 131-138.
39. Böhm M, Wieland I. Analysis of tumour-specific alterations in native specimens by PCR: how to procure the tumour cells. Int J Oncol 1997, 10, 131-139.
40. Jung K, Lein M, Ulbrich N, et al. Quantification of matrix metalloproteinases and tissue inhibitors of metalloproteinases in prostatic tissue: analytical aspects. Prostate 1998, 34, 130-136.
41. Albini A, Iwamoto Y, Kleinman HK, et al. A rapid in vitro assay for quantitating the invasive potential of tumor cells. Cancer Res 1987, 47, 3239-3245.